Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06603246 · ClinicalTrials.gov registry record · Phase 1

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

A Phase 1 study of Chronic Obstructive Pulmonary Disease and Non-cystic Fibrosis Bronchiectasis, sponsored by Genentech.

Recruiting
Registry status
Phase 1
Development phase
128
Enrollment target
7
Study locations

NCT06603246 is a Phase 1 study of Chronic Obstructive Pulmonary Disease and Non-cystic Fibrosis Bronchiectasis that is actively recruiting participants, run by Genentech. The registered enrollment target is 128 participants, below the 1,752-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06603246, a Phase 1 study of Chronic Obstructive Pulmonary Disease and Non-cystic Fibrosis Bronchiectasis, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 1
Development phase
128 participants
Enrollment target
7
Study locations

Study Summary

This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.

Conditions Studied

Chronic Obstructive Pulmonary Disease Non-cystic Fibrosis Bronchiectasis

Interventions

  • DRUG GDC-6988

Study Locations (7)

Alabama

  • University of Alabama at Birmingham - Birmingham
  • Accel Research Site - Achieve - Birmingham - ERN - PPDS - Vestavia Hills

California

  • Stanford Center for Excellence in Pulmonary Biology - Palo Alto

Kansas

  • University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd - Kansas City

North Carolina

  • University of North Carolina Clinical Research Center - Chapel Hill

Pennsylvania

  • UPMC Montefiore Hospital - Pittsburgh

Texas

  • TTS Research - Boerne

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2024-11-18
Est. Completion 2027-11-15
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06603246

The ClinicalTrials.gov registry entry for NCT06603246 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,752-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (93% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which GDC-6988 is the first listed.

NCT06603246 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Alabama, California, Kansas.

Frequently Asked Questions

What is clinical trial NCT06603246 about?

NCT06603246 is a clinical study titled "A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease". This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.

What is the current status of trial NCT06603246?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2024-11-18. Estimated completion is 2027-11-15.

What conditions does trial NCT06603246 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis.

What interventions are being tested in trial NCT06603246?

The interventions under investigation include: GDC-6988 (DRUG).

Who is sponsoring clinical trial NCT06603246?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06603246 being conducted?

This trial has 7 study locations across Alabama, California, Kansas, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Obstructive Pulmonary Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Obstructive Pulmonary Disease

All registered trials for this condition

Non-cystic Fibrosis Bronchiectasis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.